On 4 and 5 May 2026, Basel once again became a meeting point for the international biotech community during Swiss Biotech Day. This year’s edition gathered more than 3,500 participants, over 130 exhibitors and 25 international delegations. Valais was represented by Economic Promotion Valais, BioArk and HES-SO Valais/Wallis. For the Valais delegation, the objective was […]
The Swiss Biotech Report 2026 highlights Switzerland’s strong biotech performance and the growing role of Valais in bioproduction, applied research and life sciences innovation.
The third edition of Venture Technology Connect will take place on November 4, 2026, in Le Châble (Verbier). The event brings together startups and private investors in a setting designed to facilitate direct exchanges and structured discussions. A format focused on investor-startup interactions The program combines several formats aimed at fostering connections: keynote presentations pre-arranged
Venture Technology Connect returns on November 4 in Verbier Read More »
GaDia develops rapid diagnostic tests for antimicrobial resistance, combining product innovation, regulatory progress and research partnerships.
GaDia advances rapid diagnostics for antimicrobial resistance Read More »
Integrated into the Bachem Group since 2001, the Vionnaz site brings over five decades of expertise in small molecule synthesis to Valais’ pharmaceutical manufacturing landscape. Its competencies in amino acid chemistry, electrochemistry and biocatalysis position it as a specialized contributor within Bachem’s global production network.
Bachem Vionnaz: Fine chemistry capabilities, supporting complex API manufacturing Read More »
Bioscibex, a biotech startup based at BioArk Monthey, has reached the semi-finals of the >>venture>> 2026 competition, one of Switzerland’s leading startup prizes.
Bioscibex reaches semi-finals of one of Switzerland’s leading startup competitions Read More »
A recent ACS Sensors study shows how signal amplification improves the sensitivity of point-of-care diagnostic assays, enabling faster and more reliable detection of low-concentration biomarkers.
Enhancing diagnostic sensitivity for real-world use Read More »
A new cross-border project supported by the Interreg VI-A Italy–Switzerland program has been launched to address antimicrobial resistance (AMR), a growing challenge for healthcare systems.
Notrixx, a startup from HES-SO Valais based in Sion, develops a biomarker-based test to improve detection of bacterial contamination in pharmaceuticals.
Notrixx advances biomarker-based detection of bacterial contamination in pharmaceuticals Read More »
Established in 1983 in Gamsen (Brig-Glis), Valsynthèse is a Valais-based company specializing in fine chemical synthesis and high-risk chemical processes. As a subsidiary of Société Suisse des Explosifs (SSE), the company operates at the interface of complex chemistry, industrial safety, and custom manufacturing for demanding applications.
Valsynthèse: Industrial Expertise in Fine and High-Risk Chemistry Rooted in Valais Read More »
